Marshall Edwards

MEI Appoints New Director

Marshall Edwards, Inc.
04 August 2003


LSE: AIM release
5 August, 2003


MARSHALL EDWARDS INC.  APPOINTS NEW DIRECTOR

(Washington DC: August 4 2003)  The Board of Marshall Edwards Inc. (MEI) has
appointed Mr Stephen Breckenridge as a non-executive director.

Mr Breckenridge was a partner of KPMG for 24 years, in corporate taxation,
specialising in transfer pricing.

Since 2001, Mr Breckenridge has been principal of his own practice focusing on
the provision of independent tax and management advice to multi-national
corporations and SMEs.

Mr Breckenridge holds a Masters degree in Tax from the University of Sydney, is
a Fellow of the Institute of Chartered Accountants and the Taxation Institute of
Australia.

The chairman of MEI, Dr Graham Kelly, said Mr Breckenridge's international
business experience would be of significant value as the Company began
commercialising drugs, including the in-licensed novel anti-cancer compound
phenoxodiol, now in phase II clinical trials.

MEI, is incorporated in the US State of Delaware and its shares are traded on
the London Stock Exchange's, Alternate Investment Market (AIM).

The Company is 95 per cent owned by Novogen Limited (NASDAQ: NVGN), with the
balance of the shareholding held by international institutions and investors who
participated in a US$10 million capital raising, when the Company listed in May
2002.

Mr Breckenridge joins a board comprising chairman Dr Graham Kelly, non-executive
directors Mr Philip Johnston, Professor Paul Nestel AO and Professor David de
Kretser AO, and executive director and President, Mr Christopher Naughton.

More information on phenoxodiol and on the Company can be found at
www.marshalledwardsInc com and www.novogen.com.






ISSUED FOR                         :                MARSHALL EDWARDS INC



FOR FURTHER                                      CHRISTOPHER NAUGHTON, PRESIDENT

INFORMATION                      :                TEL +61 2 8877 6196

                                                                DAVID SHEON
TEL +1 202 518 6384



                      This information is provided by RNS
            The company news service from the London Stock Exchange